OverviewSuggest Edit

Kyowa Kirin (formerly Kyowa Hakko Kirin) is a pharmaceutical company focused on the areas of oncology, nephrology, immunology, and the central nervous system. It specializes in therapeutic antibodies, small molecule drugs, therapeutic nucleic acids, and regenerative medicine. The company was formed as a result of a merger between Kyowa Hakko and Kirin Pharma.
TypePublic
Founded2008
HQTH
Websitekyowakirin.com

Latest Updates

Employees (est.) (Dec 2020)5,423(-25%)
Job Openings65
Share Price (Jul 2021)$30.4
Cybersecurity ratingCMore

Key People/Management at Kyowa Kirin

Shintaro Hasegawa

Shintaro Hasegawa

President and Chief Executive Officer
Noriya Yokota

Noriya Yokota

Director of the Board
Yutaka Osawa

Yutaka Osawa

Representative Director Executive Vice President
Akira Morita

Akira Morita

Director of the Board
Yuko Haga

Yuko Haga

Director of the Board
Show more

Kyowa Kirin Office Locations

Kyowa Kirin has an office in
Show all (1)

Kyowa Kirin Financials and Metrics

Kyowa Kirin Revenue

Market capitalization (21-Jul-2021)

18.9b

Closing stock price (21-Jul-2021)

30.4
Kyowa Kirin's current market capitalization is $18.9 b.
Show all financial metrics

Kyowa Kirin Cybersecurity Score

Cybersecurity ratingPremium dataset

C

78/100

SecurityScorecard logo

Kyowa Kirin Online and Social Media Presence

Embed Graph

Kyowa Kirin News and Updates

MEI Pharma and Kyowa Kirin Announce Completion of Patient Enrollment in Follicular Lymphoma Primary Efficacy Population of Global Phase 2 TIDAL Study Intended to Support Potential Accelerated Approval Application from U.S. Food and Drug Administration (FDA)

SAN DIEGO, April 13, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, and Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a global specialty pharmaceutical company that strives to create new...

Cerecor Announces New Worldwide License Agreement with Kyowa Kirin for Anti-LIGHT Antibody CERC-002

ROCKVILLE, Md., March 29, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, today announced that its wholly-owned subsidiary, Aevi Genomic Medicine, LLC…

Helsinn and Kyowa Kirin Asia Pacific sign exclusive license and distribution agreement to strengthen their presence in Asia Pacific’s rare disease therapy area

Helsinn and Kyowa Kirin Asia Pacific sign exclusive license and distribution agreement to strengthen their presence in Asia Pacific’s rare disease therapy area

Kyowa Kirin Frequently Asked Questions

  • When was Kyowa Kirin founded?

    Kyowa Kirin was founded in 2008.

  • Who are Kyowa Kirin key executives?

    Kyowa Kirin's key executives are Shintaro Hasegawa, Noriya Yokota and Yutaka Osawa.

  • How many employees does Kyowa Kirin have?

    Kyowa Kirin has 5,423 employees.

  • Who are Kyowa Kirin competitors?

    Competitors of Kyowa Kirin include Jiangsu Hansoh Pharmaceutical Group, 3sbio and Takeda Oncology.

  • Where are Kyowa Kirin offices?

    Kyowa Kirin has an office in.

  • How many offices does Kyowa Kirin have?

    Kyowa Kirin has 1 office.